The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
Open accessAbstract
Importance: In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 13%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history of prostate cancer have an increased risk of prostate cancer compared with other men. Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer. The USPSTF also commissioned a review of existing decision analysis models and the overdiagnosis rate of PSA-based screening. The reviews also examined the benefits and harms of PSA-based screening in patient subpopulations at higher risk of prostate cancer, including older men, African American men, and men with a family history of prostate cancer. Findings: Adequate evidence from randomized clinical trials shows that PSA-based screening programs in men aged 55 to 69 years may prevent approximately 1.3 deaths from prostate cancer over approximately 13 years per 1000 men screened. Screening programs may also prevent approximately 3 cases of metastatic prostate cancer per 1000 men screened. Potential harms of screening include frequent false-positive results and psychological harms. Harms of prostate cancer treatment include erectile dysfunction, urinary incontinence, and bowel symptoms. About 1 in 5 men who undergo radical prostatectomy develop long-term urinary incontinence, and 2 in 3 men will experience long-term erectile dysfunction. Adequate evidence shows that the harms of screening in men older than 70 years are at least moderate and greater than in younger men because of increased risk of false-positive results, diagnostic harms from biopsies, and harms from treatment. The USPSTF concludes with moderate certainty that the net benefit of PSA-based screening for prostate cancer in men aged 55 to 69 years is small for some men. How each man weighs specific benefits and harms will determine whether the overall net benefit is small. The USPSTF concludes with moderate certainty that the potential benefits of PSA-based screening for prostate cancer in men 70 years and older do not outweigh the expected harms. Conclusions and Recommendation: For men aged 55 to 69 years, the decision to undergo periodic PSA-based screening for prostate cancer should be an individual one and should include discussion of the potential benefits and harms of screening with their clinician. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of family history, race/ethnicity, comorbid medical conditions, patient values about the benefits and harms of screening and treatment-specific outcomes, and other health needs. Clinicians should not screen men who do not express a preference for screening. (C recommendation) The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older. (D recommendation).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., & Hemminki, K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007133430201 · Cited by 4,114
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., Davis, M., Peters, T. J., Turner, E. L., Martin, R. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606220 · Cited by 2,640
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
American Academy of Family Physicians
(1966) · New England Journal of Medicine · doi:10.1056/nejm196611172752014 · Cited by 1,948
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,770
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Määttänen, L., Lilja, H., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60525-0 · Cited by 1,566
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Donovan, J. L., Hamdy, F. C., Lane, J. A., Mason, M., Metcalfe, C., Walsh, E., Blazeby, J. M., Peters, T. J., Holding, P., Bonnington, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606221 · Cited by 1,338
Early Detection of Prostate Cancer: AUA Guideline
Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.119 · Cited by 1,242
Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Garmo, H., Rider, J. R., Taari, K., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Spångberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311593 · Cited by 981
Ryerson, A. B., Eheman, C. R., Altekruse, S. F., Ward, J. W., Jemal, A., Sherman, R. L., Henley, S. J., Holtzman, D., Lake, A., Noone, A., et al. (2016) · Cancer · doi:10.1002/cncr.29936 · Cited by 945
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
Wilt, T. J., Jones, K. M., Barry, M. J., Andriole, G. L., Culkin, D., Wheeler, T., Aronson, W. J., & Brawer, M. K. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615869 · Cited by 623
Trends in Management for Patients With Localized Prostate Cancer, 1990-2013
Cooperberg, M. R., & Carroll, P. R. (2015) · JAMA · doi:10.1001/jama.2015.6036 · Cited by 609
Fenton, J. J., Weyrich, M. S., Durbin, S., Liu, Y., Bang, H., & Melnikow, J. (2018) · JAMA · doi:10.1001/jama.2018.3712 · Cited by 555
Prevention and early detection of prostate cancer
Cuzick, J., Thorat, M. A., Andriole, G., Brawley, O. W., Brown, P. H., Culig, Z., Eeles, R. A., Ford, L. G., Hamdy, F. C., Holmberg, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70211-6 · Cited by 495
Martin, R. M., Donovan, J. L., Turner, E. L., Metcalfe, C., Young, G. J., Walsh, E. I., Lane, J. A., Noble, S., Oliver, S. E., Evans, S., et al. (2018) · JAMA · doi:10.1001/jama.2018.0154 · Cited by 415
Johansson, E., Steineck, G., Holmberg, L., Johansson, J.-E., Nyberg, T., Ruutu, M., & Bill-Axelson, A. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70162-0 · Cited by 360
Rosario, D. J., Lane, J. A., Metcalfe, C., Donovan, J., Doble, A., Goodwin, L., Davis, M., Catto, J. W. F., AVERY, K. N. L., Neal, D. E., et al. (2012) · BMJ · doi:10.1136/bmj.d7894 · Cited by 294
Qaseem, A., Barry, M. J., Denberg, T. D., Owens, D. K., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-10-201305210-00633 · Cited by 287
Self-citationSchröder, F. H., Hugosson, J., Carlsson, S., Tammela, T., Määttänen, L., Auvinen, A., Kwiatkowski, M., Recker, F., & Roobol, M. J. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.068 · Cited by 270
Jahn, J. L., Giovannucci, E. L., & Stampfer, M. J. (2015) · International Journal of Cancer · doi:10.1002/ijc.29408 · Cited by 268
Pinsky, P. F., Prorok, P. C., Yu, K., Kramer, B. S., Black, A., Gohagan, J. K., Crawford, E. D., Grubb, R. L., & Andriole, G. L. (2017) · Cancer · doi:10.1002/cncr.30474 · Cited by 256
Pinsky, P. F., Black, A., Kramer, B. S., Miller, A. B., Prorok, P. C., & Berg, C. D. (2010) · Clinical Trials · doi:10.1177/1740774510374091 · Cited by 145
Prostate Cancer Mortality in the Finnish Randomized Screening Trial
Kilpeläinen, T. P., Tammela, T. L. J., Malila, N. K., Hakama, M., Santti, H., Määttänen, L., Stenman, U., Kujala, P. M., & Auvinen, A. P. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt038 · Cited by 112
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC
Wolters, T., Roobol, M. J., Steyerberg, E. W., van den Bergh, R. C. N., Bangma, C. H., Hugosson, J., Ciatto, S., Kwiatkowski, M., Villers, A. A., Lujan, M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24870 · Cited by 99
Fowler, F. J., Barry, M. J., Walker-Corkery, B., Caubet, J.-F., Bates, D. W., Lee, J. M., Hauser, A., & McNaughton‐Collins, M. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00464.x · Cited by 79
Health Perceptions in Patients Who Undergo Screening and Workup for Prostate Cancer
Katz, D. A., Jarrard, D. F., McHorney, C. A., Hillis, S. L., Wiebe, D. A., & Fryback, D. G. (2007) · Urology · doi:10.1016/j.urology.2006.09.059 · Cited by 61
Brindle, L. A., Oliver, S. E., Dedman, D., Donovan, J., Neal, D. E., Hamdy, F. C., Lane, J. A., & Peters, T. J. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06401.x · Cited by 55
Cited by
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Metadata
- Authors
- US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Bibbins-Domingo, K., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Ebell, M., Epling, J. W., Kemper, A. R., Krist, A. H., Kubik, M., Landefeld, C. S., Mangione, C. M., Silverstein, M., Simon, M. A., Siu, A. L., & Tseng, C.-W.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2018-05-08
- Volume
- 319
- Issue
- 18
- Pages
- 1901
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2966258052
- Cited by
- 1,436
- References
- 28
- FWCI
- 90.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.